MA29773B1 - Derives de 1-h-pyrrole substitues par un groupe 1-heterocyclysulfonyle, 2-aminomethyle, 5-(hetero) aryle en tant qu'inhibiteurs des secretions acides - Google Patents
Derives de 1-h-pyrrole substitues par un groupe 1-heterocyclysulfonyle, 2-aminomethyle, 5-(hetero) aryle en tant qu'inhibiteurs des secretions acidesInfo
- Publication number
- MA29773B1 MA29773B1 MA30739A MA30739A MA29773B1 MA 29773 B1 MA29773 B1 MA 29773B1 MA 30739 A MA30739 A MA 30739A MA 30739 A MA30739 A MA 30739A MA 29773 B1 MA29773 B1 MA 29773B1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- optionally substituted
- optionally
- aryl
- heterocyclysulfonyl
- Prior art date
Links
- 230000009858 acid secretion Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Abstract
La présente invention concerne un composé ayant un effet inhibiteur des sécrétions acides supérieur et présentant une activité antiulcéreuse et similaire. La présente invention concerne un composé représenté par la formule (I) dans laquelle R1 est un groupe hétérocyclique monocyclique contenant de l'azote facultativement condensé avec un cycle benzénique ou un hétérocycle, le groupe hétérocyclique monocyclique contenant de l'azote facultativement condensé avec un cycle benzénique ou un hétérocycle a facultativement un ou plusieurs substituants, R2 est un groupe aryle en C6-14 facultativement substitué, un groupe thiényle facultativement substitué ou un groupe pyridyle facultativement substitué, R3 et R4 sont chacun un atome d'hydrogène ou l'un de R3 et R4 est un atome d'hydrogène et l'autre est un groupe alkyle inférieur facultativement substitué, un groupe acyle, un atome d'halogène, un groupe cyano ou un groupe nitro, et R5 est un groupe alkyle ou un sel de celui-ci.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005250356 | 2005-08-30 | ||
| JP2006100626 | 2006-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29773B1 true MA29773B1 (fr) | 2008-09-01 |
Family
ID=37517870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30739A MA29773B1 (fr) | 2005-08-30 | 2008-03-11 | Derives de 1-h-pyrrole substitues par un groupe 1-heterocyclysulfonyle, 2-aminomethyle, 5-(hetero) aryle en tant qu'inhibiteurs des secretions acides |
Country Status (32)
| Country | Link |
|---|---|
| US (7) | US7498337B2 (fr) |
| EP (2) | EP2327692B9 (fr) |
| JP (3) | JP4035559B1 (fr) |
| KR (2) | KR101115857B1 (fr) |
| CN (1) | CN101300229B (fr) |
| AR (1) | AR055144A1 (fr) |
| AT (1) | ATE504567T1 (fr) |
| AU (1) | AU2006285641A1 (fr) |
| BR (2) | BRPI0615111B8 (fr) |
| CA (1) | CA2621182C (fr) |
| CR (1) | CR9755A (fr) |
| CY (2) | CY1111922T1 (fr) |
| DE (1) | DE602006021195D1 (fr) |
| DK (2) | DK2327692T5 (fr) |
| ES (2) | ES2364498T3 (fr) |
| GE (1) | GEP20105044B (fr) |
| HR (2) | HRP20110473T1 (fr) |
| IL (1) | IL189375A (fr) |
| JO (1) | JO2791B1 (fr) |
| MA (1) | MA29773B1 (fr) |
| ME (1) | MEP10009A (fr) |
| NO (1) | NO341894B1 (fr) |
| NZ (1) | NZ566378A (fr) |
| PE (2) | PE20110009A1 (fr) |
| PL (2) | PL1919865T3 (fr) |
| PT (2) | PT2327692E (fr) |
| RS (2) | RS52473B9 (fr) |
| SI (2) | SI2327692T1 (fr) |
| TW (1) | TWI358296B (fr) |
| UA (1) | UA94424C2 (fr) |
| WO (1) | WO2007026916A1 (fr) |
| ZA (1) | ZA200802488B (fr) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101115857B1 (ko) * | 2005-08-30 | 2012-04-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 산 분비 억제제로서 1-헤테로시클릴술포닐, 2-아미노메틸,5-(헤테로-) 아릴 치환된 1-h-피롤 유도체 |
| US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| JP5345140B2 (ja) * | 2007-09-28 | 2013-11-20 | 武田薬品工業株式会社 | プロトンポンプ阻害剤としての5員複素環化合物 |
| JP5379690B2 (ja) | 2007-09-28 | 2013-12-25 | 武田薬品工業株式会社 | 5員複素環化合物 |
| US8309580B2 (en) | 2007-11-01 | 2012-11-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN104784180A (zh) * | 2008-07-28 | 2015-07-22 | 武田药品工业株式会社 | 药物组合物 |
| WO2010021149A1 (fr) * | 2008-08-21 | 2010-02-25 | 武田薬品工業株式会社 | Composé spiro capable d'inhiber une sécrétion d'acide |
| NZ591793A (en) | 2008-08-27 | 2012-11-30 | Takeda Pharmaceutical | Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds |
| CN108129374A (zh) * | 2009-02-25 | 2018-06-08 | 武田药品工业株式会社 | 制备吡咯化合物的方法 |
| WO2010110378A1 (fr) | 2009-03-26 | 2010-09-30 | 武田薬品工業株式会社 | Composé pyrazole |
| EP2452680B1 (fr) | 2009-07-09 | 2019-12-18 | RaQualia Pharma Inc. | Antagoniste de la pompe à acide destiné au traitement de maladies associées à un transit gastro-intestinal anormal |
| WO2012095691A1 (fr) * | 2011-01-15 | 2012-07-19 | Jubilant Life Sciences Ltd. | Procédé amélioré pour la production d'aminopyridines |
| CN102863371B (zh) * | 2011-07-06 | 2016-04-13 | 中国科学院上海有机化学研究所 | 氟代二氢吡咯或氟代吡咯 |
| NZ703528A (en) * | 2012-06-27 | 2016-08-26 | Takeda Pharmaceutical | Liquid preparations of amines and organic acids stabilized by salts |
| CN104039776B (zh) * | 2012-08-03 | 2016-06-08 | 上海恒瑞医药有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
| JP6292736B2 (ja) * | 2012-11-19 | 2018-03-14 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | ピロールスルホンアミド誘導体、その製造法およびその医療用途 |
| JP6343600B2 (ja) | 2013-02-28 | 2018-06-13 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| KR102129842B1 (ko) | 2013-10-02 | 2020-07-06 | 주식회사 대웅제약 | 술포닐인돌 유도체 및 이의 제조방법 |
| CN103951652B (zh) * | 2014-04-18 | 2015-09-23 | 潍坊博创国际生物医药研究院 | 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲胺水溶性有机酸盐和注射剂及它们的制备方法 |
| CN105367550A (zh) * | 2014-08-11 | 2016-03-02 | 江苏柯菲平医药股份有限公司 | 四氢环戊二烯并[c]吡咯类衍生物、其制备方法及其在医药上的应用 |
| CN105646451A (zh) * | 2014-11-12 | 2016-06-08 | 江苏豪森药业集团有限公司 | 钾离子竞争性酸阻滞剂的晶型及其制备方法 |
| CN107001262A (zh) * | 2014-11-19 | 2017-08-01 | 江苏豪森药业集团有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其晶型、中间体和医药用途 |
| CN104447491B (zh) * | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
| CN106957252B (zh) * | 2014-11-19 | 2019-11-19 | 连云港恒运药业有限公司 | 一种质子泵抑制剂中间体及其制备方法 |
| CN105693693A (zh) * | 2014-11-27 | 2016-06-22 | 江苏柯菲平医药股份有限公司 | 一种吡咯类胃酸分泌和抑制剂化合物盐的制备 |
| CN104356043B (zh) * | 2014-11-27 | 2016-10-26 | 重庆威尔德浩瑞医药化工有限公司 | 一种制备5-(2-氟苯基)-1h-吡咯-3-甲醛的方法 |
| CN105708812A (zh) * | 2014-12-02 | 2016-06-29 | 江苏柯菲平医药股份有限公司 | 一种5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲氨冻干粉针及其制备方法 |
| CN104860923B (zh) * | 2015-01-21 | 2018-01-12 | 山东康美乐医药科技有限公司 | 富马酸沃诺拉赞的制备方法 |
| CN105985278A (zh) * | 2015-01-27 | 2016-10-05 | 江苏柯菲平医药股份有限公司 | 吡咯磺酰类衍生物、其制备方法及其在医药上的应用 |
| CN105982867A (zh) * | 2015-02-27 | 2016-10-05 | 江苏柯菲平医药股份有限公司 | 一种h009冻干粉针及其制备方法 |
| CN106031710B (zh) * | 2015-03-16 | 2019-03-12 | 南京优科制药有限公司 | 一种富马酸氟呐普拉赞的注射剂及其制备方法 |
| CN104814964B (zh) * | 2015-04-16 | 2018-07-31 | 广东赛烽医药科技有限公司 | 一种抗胃幽门螺旋杆菌的药物组合物、制备方法及其应用 |
| KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| CN105315258A (zh) * | 2015-05-16 | 2016-02-10 | 南京海纳医药科技有限公司 | 富马酸沃诺拉赞多晶型及其制备方法 |
| CN104860926B (zh) * | 2015-06-10 | 2017-06-30 | 浙江诚意药业股份有限公司 | 一种富马酸沃诺拉赞的制备方法 |
| CN104945313A (zh) * | 2015-06-19 | 2015-09-30 | 洪帅金 | 一种2-甲基-3-溴吡啶的制备方法 |
| CN104926790B (zh) * | 2015-06-29 | 2017-07-07 | 江苏奥赛康药业股份有限公司 | 一种高纯度Vonoprazan Fumarate化合物及其中间体、杂质以及它们的制备方法 |
| WO2017002849A1 (fr) | 2015-06-30 | 2017-01-05 | 武田薬品工業株式会社 | Procédé de production d'un composé pyrrole |
| CN104974082A (zh) * | 2015-07-26 | 2015-10-14 | 陈吉美 | 一种2-甲基-4-溴吡啶的制备方法 |
| CN106432191A (zh) * | 2015-08-10 | 2017-02-22 | 陕西合成药业股份有限公司 | 一种新的吡咯类衍生物、其制备方法及其在医药上的应用 |
| CN105106203B (zh) * | 2015-08-17 | 2019-04-05 | 江苏豪森药业集团有限公司 | 富马酸沃诺拉赞的药物组合物及其制备方法 |
| CN105085484B (zh) * | 2015-08-21 | 2017-11-24 | 南京济群医药科技股份有限公司 | 一种富马酸沃诺拉赞的制备方法 |
| CN105030720B (zh) * | 2015-08-26 | 2019-12-10 | 迪沙药业集团有限公司 | 一种富马酸沃诺拉赞肠溶片及其制备方法 |
| CN105030725B (zh) * | 2015-08-26 | 2019-12-10 | 迪沙药业集团有限公司 | 一种富马酸沃诺拉赞肠溶组合物及其制备方法 |
| CN106478597A (zh) * | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技(武汉)有限公司 | 富马酸沃诺拉赞单晶及其制备方法和用途 |
| CN106511344A (zh) * | 2015-09-14 | 2017-03-22 | 王虹 | 一种胃酸分泌抑制剂的新用途 |
| CN106632246A (zh) * | 2015-10-30 | 2017-05-10 | 江苏柯菲平医药股份有限公司 | 一种吡咯类胃酸分泌抑制剂化合物盐的晶型及其制备 |
| CN105198802A (zh) * | 2015-11-03 | 2015-12-30 | 江苏梦得电镀化学品有限公司 | 一种2-甲基-3-溴吡啶的制备方法 |
| CN105294653B (zh) * | 2015-11-16 | 2017-08-15 | 山东罗欣药业集团股份有限公司 | 富马酸沃诺拉赞的制备工艺 |
| CN105440019A (zh) * | 2015-12-17 | 2016-03-30 | 昆明贵研药业有限公司 | 一种治疗胃酸疾病药物的制备方法 |
| CN105503828A (zh) * | 2015-12-24 | 2016-04-20 | 北京康立生医药技术开发有限公司 | 一种吡咯衍生物的富马酸盐的制备方法 |
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR20170113040A (ko) | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| CN106074406A (zh) * | 2016-06-12 | 2016-11-09 | 佛山市腾瑞医药科技有限公司 | 一种富马酸沃诺拉赞分散片及其制备方法 |
| CN108191830B (zh) * | 2016-06-30 | 2019-06-14 | 珠海赛隆药业股份有限公司(长沙)医药研发中心 | 一种富马酸沃诺拉赞中间体ⅳ及其制备方法 |
| KR101777971B1 (ko) | 2016-07-05 | 2017-09-12 | 제일약품주식회사 | 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도 |
| CN106187852B (zh) * | 2016-07-07 | 2019-01-15 | 江西同和药业股份有限公司 | 一种富马酸沃诺拉赞中间体的制备方法 |
| CN106431871A (zh) * | 2016-08-17 | 2017-02-22 | 济南贝莱尔化学科技有限公司 | 一种2′‑溴代邻氟苯乙酮的制备方法 |
| CN106243008B (zh) * | 2016-08-22 | 2018-09-04 | 山东金城生物药业有限公司 | 富马酸沃诺拉赞中间体5-(2-氟苯基)-1h-吡咯-3-甲醛的制备方法 |
| CN107778207A (zh) * | 2016-08-25 | 2018-03-09 | 广东东阳光药业有限公司 | 富马酸沃诺拉赞中间体及其制备方法和用途 |
| CN106397404A (zh) * | 2016-08-31 | 2017-02-15 | 山东新华制药股份有限公司 | 5‑(2‑氟苯基)‑1‑(吡啶‑3‑基磺酰基)‑1h‑吡咯‑3‑甲醛的制备方法 |
| CN106380464A (zh) * | 2016-08-31 | 2017-02-08 | 山东新华制药股份有限公司 | 氟呐普拉赞关键中间体的制备方法 |
| CN115385845B (zh) * | 2016-09-12 | 2024-07-26 | 江苏柯菲平医药股份有限公司 | 一种吡咯磺酸类化合物盐型制备 |
| CN107879964B (zh) * | 2016-09-29 | 2023-02-10 | 江苏柯菲平医药股份有限公司 | 1-(5-(2-氟苯基)-1-(3-(3-甲氧丙氧基)苯磺酰氯)-1h-吡咯-3-基)-n-甲基胺的制备方法 |
| CN108069891B (zh) * | 2016-11-16 | 2022-09-20 | 江苏柯菲平医药股份有限公司 | 一类甲基甲胺盐酸盐的a晶型、制备及其应用 |
| CN106892900A (zh) * | 2017-04-10 | 2017-06-27 | 山东裕欣药业有限公司 | 一种富马酸沃诺拉赞及其制备方法 |
| CN106905216A (zh) * | 2017-04-19 | 2017-06-30 | 刘德鹏 | 一种质子泵抑制剂药物化合物及其制备方法 |
| CN107011327A (zh) * | 2017-04-19 | 2017-08-04 | 刘德鹏 | 一种治疗消化性溃疡的药物化合物及其制备方法 |
| CN108794449B (zh) * | 2017-05-05 | 2023-08-04 | 广东东阳光药业有限公司 | 一种氘代富马酸沃诺拉赞代谢物的合成方法 |
| KR102233455B1 (ko) | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| MY200542A (en) * | 2017-07-10 | 2024-01-02 | Takeda Pharmaceuticals Co | Preparation comprising vonoprazan |
| KR20190057569A (ko) | 2017-11-20 | 2019-05-29 | 제일약품주식회사 | 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도 |
| KR102500124B1 (ko) * | 2017-12-27 | 2023-02-14 | 닛뽕 케미파 가부시키가이샤 | 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1h-피롤-3-일]-n-메틸메탄아민모노푸마르산염의 제조법 |
| CN108558831B (zh) * | 2018-06-08 | 2021-07-27 | 上海璃道医药科技有限公司 | 取代吡咯-4-烷基胺类化合物及其用途 |
| CN109053684A (zh) * | 2018-08-09 | 2018-12-21 | 珠海润都制药股份有限公司 | 一种富马酸沃诺拉赞及其中间体的制备方法 |
| KR102126576B1 (ko) | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| CN110272409A (zh) * | 2019-03-11 | 2019-09-24 | 南京百迪尔生物医药有限公司 | 一步法合成沃诺拉赞的新方法 |
| KR102222443B1 (ko) | 2019-04-11 | 2021-03-03 | 일동제약(주) | 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1h-피롤-3-일]-n-메틸메탄아민의 신규염, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| CN112300123B (zh) * | 2019-08-02 | 2023-07-18 | 上海天慈国际药业有限公司 | 一种沃诺拉赞中间体的制备方法 |
| CN110590746B (zh) * | 2019-09-23 | 2023-08-29 | 吉林汇康制药有限公司 | 一种低杂质富马酸沃诺拉赞的制备方法 |
| CN110627628A (zh) * | 2019-09-24 | 2019-12-31 | 上海应用技术大学 | 一种β-碘代二氟丙酮类衍生物及其制备方法 |
| WO2021104256A1 (fr) * | 2019-11-25 | 2021-06-03 | 杭州华东医药集团新药研究院有限公司 | Dérivé hétérocylique, composition pharmaceutique et utilisation associées |
| CN111018835B (zh) * | 2019-12-16 | 2022-09-20 | 株洲千金药业股份有限公司 | 一种沃诺拉赞的纯化方法 |
| CN113527536B (zh) * | 2020-04-21 | 2024-03-22 | 杭州德柯医疗科技有限公司 | 一种含氟多糖高分子化合物及其制备方法 |
| CN114349737B (zh) * | 2020-04-26 | 2023-06-09 | 南京烁慧医药科技有限公司 | 一种含磺酰胺结构的化合物及其应用、一种药物组合物及其应用 |
| CN111484458B (zh) * | 2020-05-25 | 2022-12-27 | 南京竹园医药科技有限公司 | 一种2-羟基-5-磺酸基嘧啶的制备方法 |
| PT4148050T (pt) * | 2020-06-17 | 2025-01-29 | Ildong Pharmaceutical Co Ltd | Novo inibidor da secreção ácida e sua utilização |
| CN111943932B (zh) * | 2020-08-06 | 2023-07-14 | 四川国康药业有限公司 | 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途 |
| CN114149411B (zh) * | 2020-09-08 | 2025-05-16 | 鲁南制药集团股份有限公司 | 一种沃诺拉赞中间体及其制备方法与应用 |
| CN112812099B (zh) * | 2021-01-19 | 2022-04-26 | 珠海赛隆药业股份有限公司 | 一种用于治疗消化性溃疡的化合物及其制法和用途 |
| CN114989138B (zh) * | 2021-03-02 | 2023-06-13 | 天地恒一制药股份有限公司 | 沃诺拉赞盐及其晶型、制备方法和用途 |
| CN116239606B (zh) * | 2021-07-09 | 2025-09-02 | 天地恒一制药股份有限公司 | 一种吡咯磺酰类衍生物、及其制备方法与应用 |
| CN115594622B (zh) * | 2021-07-09 | 2025-03-21 | 天地恒一制药股份有限公司 | 一种吡咯磺酰类衍生物、及其制备方法与应用 |
| CN113620930B (zh) * | 2021-07-12 | 2022-08-16 | 南京烁慧医药科技有限公司 | 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用 |
| CN114105962B (zh) * | 2021-10-26 | 2024-11-05 | 南京烁慧医药科技有限公司 | 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用 |
| WO2023113458A1 (fr) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Nouveau sel de dérivé de 1-sulfonyle pyrrole, son procédé de préparation et composition pharmaceutique le comprenant |
| KR20230102353A (ko) * | 2021-12-30 | 2023-07-07 | 주식회사 대웅제약 | 삼중음성유방암의 예방 또는 치료용 약학적 조성물 |
| KR102749187B1 (ko) | 2022-01-24 | 2025-01-03 | 순천향대학교 산학협력단 | 칼륨 경쟁적 위산분비 억제제의 신규한 공결정, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| CN115232107A (zh) * | 2022-07-29 | 2022-10-25 | 南京唯创远医药科技有限公司 | 一种高纯度富马酸伏诺拉生的制备方法 |
| US12060148B2 (en) | 2022-08-16 | 2024-08-13 | Honeywell International Inc. | Ground resonance detection and warning system and method |
| CN116023364A (zh) * | 2023-01-31 | 2023-04-28 | 山东铂源药业股份有限公司 | 一种富马酸沃诺拉赞的制备方法 |
| KR102974932B1 (ko) * | 2023-07-21 | 2026-06-09 | 한림제약(주) | 보노프라잔 푸마르산염의 제조방법 |
| CN117050009B (zh) * | 2023-08-17 | 2026-06-16 | 台州臻挚生物科技有限公司 | 一种4-三氟甲基吡啶中间体核心母核及其衍生物的制备方法 |
| CN119528787A (zh) * | 2023-08-31 | 2025-02-28 | 上海柏狮生物科技有限公司 | 以异腈和Michael受体制备一系列沃诺拉赞中间体的方法 |
| KR20250095434A (ko) | 2023-12-19 | 2025-06-26 | 주식회사 경보제약 | 보노프라잔 토실레이트 염, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| CN117462507B (zh) * | 2023-12-28 | 2024-03-15 | 山东齐都药业有限公司 | 富马酸伏诺拉生药物组合物及其制备方法 |
| CN118108705A (zh) * | 2024-01-29 | 2024-05-31 | 浙江工业大学 | 一种富马酸沃诺拉赞的制备方法 |
| IT202400004474A1 (it) | 2024-02-29 | 2025-08-29 | Dipharma Francis Srl | Metodo di purificazione di un farmaco usato per il trattamento dell'acidità gastrica |
| KR20260020368A (ko) * | 2024-08-02 | 2026-02-11 | 일양약품주식회사 | 4-사이클로프로필 피롤 유도체 및 이의 용도 |
| KR20260082181A (ko) | 2024-11-27 | 2026-06-04 | (주) 팜젠사이언스 | 신규한 피롤 유도체 화합물 및 이를 포함하는 위산분비 억제용 약제학적 조성물 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0259085B1 (fr) | 1986-08-29 | 1991-08-21 | Pfizer Inc. | Guanidino-2 aryl-4 thiazole pour le traitement de l'ulcère peptique |
| US5128366A (en) | 1990-07-05 | 1992-07-07 | Shinogi & Co., Ltd. | Pyrrole derivatives |
| WO1992004025A1 (fr) | 1990-08-31 | 1992-03-19 | Warner-Lambert Company | Analogues d'acides amines utilises comme antagonistes de cholecystokinine |
| HU219131B (hu) | 1991-10-18 | 2001-02-28 | Monsanto Co. | Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok |
| CN1071924A (zh) | 1991-10-29 | 1993-05-12 | 纳幕尔杜邦公司 | 除草的三唑羧酸酰胺 |
| JPH06135961A (ja) | 1992-10-23 | 1994-05-17 | Nippon Iyakuhin Kogyo Kk | 新規ジフェニルピロリルフラン誘導体 |
| US5286742A (en) * | 1992-11-03 | 1994-02-15 | American Cyanamid Company | Pyrrole thiocarboxamide insecticidal and acaricidal agents |
| US5480902A (en) * | 1993-08-31 | 1996-01-02 | American Cyanamid Company | Thienylpyrrole fungicidal agents |
| JPH08119936A (ja) | 1994-10-18 | 1996-05-14 | Fujisawa Pharmaceut Co Ltd | 複素環式誘導体 |
| JPH0930967A (ja) | 1995-07-17 | 1997-02-04 | Chugai Pharmaceut Co Ltd | 抗潰瘍剤 |
| BR9713465A (pt) | 1996-08-28 | 2000-03-28 | Procter & Gamble | Inibidores metalotprotease de amina cìclica sibstituìda |
| CA2275796A1 (fr) | 1996-12-23 | 1998-07-02 | Donald Joseph Phillip Pinto | Composes heteroaromatiques contenant de l'azote, utilises en tant qu'inhibiteurs du facteur xa |
| JPH11209344A (ja) | 1998-01-26 | 1999-08-03 | Kyowa Hakko Kogyo Co Ltd | 含窒素複素環化合物 |
| GB9817548D0 (en) * | 1998-08-12 | 1998-10-07 | Novartis Ag | Organic compounds |
| DE60020226T2 (de) | 1999-03-10 | 2006-02-02 | Shionogi & Co., Ltd. | Medizinische zubereitungen mit [2.2.1] und [3.1.1]bicycloskelett die antagonisten für sowohl pgd 2? als auch txa 2? rezeptoren sind |
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| DE19913483A1 (de) | 1999-03-25 | 2000-09-28 | Goedecke Ag | Verfahren zur Herstellung von Heterocyclischen Carbamaten aus Aza-Heterocyclen und Kohlendioxid |
| AU3783100A (en) | 1999-06-14 | 2000-12-21 | Dow Agrosciences Llc | Substituted triazoles, imidazoles and pyrazoles as herbicides |
| ES2250196T3 (es) * | 1999-08-26 | 2006-04-16 | Aventis Pharmaceuticals Inc. | Aminoiminometil o aminometil dihidrobenzofuranos y benzopiranos sustituidos. |
| US6911468B2 (en) | 2000-05-22 | 2005-06-28 | Takeda Chemical Industries, Ltd. | Tyrosine phosphatase inhibitors |
| US6589978B2 (en) | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
| GB0016453D0 (en) | 2000-07-04 | 2000-08-23 | Hoffmann La Roche | Pyrrole derivatives |
| US7544690B2 (en) | 2001-10-01 | 2009-06-09 | Taisho Pharmaceutical Co., Ltd. | MCH receptor antagonists |
| WO2003040147A1 (fr) | 2001-11-08 | 2003-05-15 | Pharmacia & Upjohn Company | Composes heteroaryles substitues azabicycliques pour le traitement de maladies |
| WO2003044011A1 (fr) | 2001-11-22 | 2003-05-30 | Ciba Specialty Chemicals Holding Inc. | Synthese de pyrroles |
| CA2471754A1 (fr) | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Antagoniste du recepteur androgene |
| WO2003068738A1 (fr) | 2002-02-11 | 2003-08-21 | Neurocrine Biosciences, Inc. | Derives de pyrrole utilises en tant que ligands de recepteurs de melanocortine |
| WO2003068740A1 (fr) | 2002-02-14 | 2003-08-21 | Wyeth | Derives de pyrrolylalkylidene-hydrazinecarboxymidamide tels que des ligands 5-hydroxytryptamine-6 |
| TW200306191A (en) | 2002-02-22 | 2003-11-16 | Teijin Ltd | Pyrrolopyrimidine derivatives |
| ES2297204T3 (es) * | 2002-05-17 | 2008-05-01 | Merckle Gmbh | Compuestos pirrolicos recocidos como inhibidores de la bomba de protones para el tratamiento de la ulcera. |
| BR0311707A (pt) | 2002-06-13 | 2005-03-15 | Du Pont | Composto, composição e método de controle de pelo menos uma praga invertebrada |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| US7186716B2 (en) | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| JP2004315511A (ja) | 2003-03-31 | 2004-11-11 | Taisho Pharmaceut Co Ltd | Mch受容体アンタゴニスト |
| US7612064B2 (en) | 2003-05-26 | 2009-11-03 | Takeda Pharmaceutical Company Limited | Sulfopyrroles |
| JP2005044740A (ja) | 2003-07-25 | 2005-02-17 | Taniguchi Heaters Kk | 空焚きセンサー内蔵の液中用ヒーター |
| JP4239860B2 (ja) | 2004-03-08 | 2009-03-18 | ヤマハ株式会社 | 擦弦楽器用駒および擦弦楽器 |
| EP1769092A4 (fr) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | Lixiviation amelioree de metaux de base |
| JP5173192B2 (ja) * | 2004-09-30 | 2013-03-27 | 武田薬品工業株式会社 | プロトンポンプ阻害薬 |
| JP2006100626A (ja) | 2004-09-30 | 2006-04-13 | Fuji Photo Film Co Ltd | 半導体発光装置 |
| EP1655284A1 (fr) | 2004-10-26 | 2006-05-10 | Aponetics AG | 2-Phenylsulfopyrroles |
| KR101115857B1 (ko) * | 2005-08-30 | 2012-04-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 산 분비 억제제로서 1-헤테로시클릴술포닐, 2-아미노메틸,5-(헤테로-) 아릴 치환된 1-h-피롤 유도체 |
| KR101366856B1 (ko) * | 2007-03-29 | 2014-02-21 | 삼성전자주식회사 | 다양한 포트를 통해 입력되는 영상을 디스플레이하는디스플레이 장치 |
-
2006
- 2006-08-29 KR KR1020087006439A patent/KR101115857B1/ko active Active
- 2006-08-29 SI SI200631443T patent/SI2327692T1/sl unknown
- 2006-08-29 WO PCT/JP2006/317408 patent/WO2007026916A1/fr not_active Ceased
- 2006-08-29 AT AT06797335T patent/ATE504567T1/de active
- 2006-08-29 RS RS20120448A patent/RS52473B9/sr unknown
- 2006-08-29 UA UAA200803949A patent/UA94424C2/ru unknown
- 2006-08-29 RS RS20110233A patent/RS51697B/sr unknown
- 2006-08-29 GE GEAP200610602A patent/GEP20105044B/en unknown
- 2006-08-29 TW TW095131827A patent/TWI358296B/zh active
- 2006-08-29 US US11/512,629 patent/US7498337B2/en active Active
- 2006-08-29 CA CA2621182A patent/CA2621182C/fr active Active
- 2006-08-29 PE PE2010001016A patent/PE20110009A1/es active IP Right Grant
- 2006-08-29 JP JP2007524121A patent/JP4035559B1/ja active Active
- 2006-08-29 ME MEP-100/09A patent/MEP10009A/xx unknown
- 2006-08-29 BR BRPI0615111A patent/BRPI0615111B8/pt active IP Right Grant
- 2006-08-29 EP EP11155996.9A patent/EP2327692B9/fr active Active
- 2006-08-29 SI SI200631038T patent/SI1919865T1/sl unknown
- 2006-08-29 US US11/991,307 patent/US7977488B2/en active Active
- 2006-08-29 NZ NZ566378A patent/NZ566378A/en unknown
- 2006-08-29 ES ES06797335T patent/ES2364498T3/es active Active
- 2006-08-29 DE DE602006021195T patent/DE602006021195D1/de active Active
- 2006-08-29 PE PE2006001053A patent/PE20070540A1/es active IP Right Grant
- 2006-08-29 AR ARP060103754A patent/AR055144A1/es active IP Right Grant
- 2006-08-29 PT PT11155996T patent/PT2327692E/pt unknown
- 2006-08-29 EP EP06797335A patent/EP1919865B1/fr active Active
- 2006-08-29 PL PL06797335T patent/PL1919865T3/pl unknown
- 2006-08-29 DK DK11155996.9T patent/DK2327692T5/da active
- 2006-08-29 BR BR122017028096A patent/BR122017028096B8/pt active IP Right Grant
- 2006-08-29 HR HR20110473T patent/HRP20110473T1/hr unknown
- 2006-08-29 ZA ZA200802488A patent/ZA200802488B/xx unknown
- 2006-08-29 PL PL11155996T patent/PL2327692T3/pl unknown
- 2006-08-29 JO JO2006287A patent/JO2791B1/en active
- 2006-08-29 DK DK06797335.4T patent/DK1919865T3/da active
- 2006-08-29 PT PT06797335T patent/PT1919865E/pt unknown
- 2006-08-29 CN CN2006800407897A patent/CN101300229B/zh active Active
- 2006-08-29 KR KR1020117017886A patent/KR101408561B1/ko active Active
- 2006-08-29 ES ES11155996T patent/ES2391757T3/es active Active
- 2006-08-29 AU AU2006285641A patent/AU2006285641A1/en not_active Abandoned
-
2007
- 2007-06-12 JP JP2007155692A patent/JP5204426B2/ja active Active
-
2008
- 2008-02-07 IL IL189375A patent/IL189375A/en active IP Right Grant
- 2008-02-22 CR CR9755A patent/CR9755A/es unknown
- 2008-03-11 MA MA30739A patent/MA29773B1/fr unknown
- 2008-03-25 NO NO20081464A patent/NO341894B1/no unknown
-
2009
- 2009-01-26 US US12/359,762 patent/US8415368B2/en active Active
-
2011
- 2011-03-01 US US13/037,690 patent/US8338461B2/en active Active
- 2011-06-08 US US13/156,216 patent/US8299261B2/en active Active
- 2011-06-08 US US13/156,204 patent/US8436187B2/en active Active
- 2011-06-08 US US13/156,226 patent/US8338462B2/en active Active
- 2011-06-30 CY CY20111100637T patent/CY1111922T1/el unknown
-
2012
- 2012-10-03 HR HRP20120792TT patent/HRP20120792T1/hr unknown
- 2012-10-12 CY CY20121100943T patent/CY1114415T1/el unknown
-
2013
- 2013-01-08 JP JP2013001273A patent/JP5687293B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA94424C2 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | |
| MA27626A1 (fr) | Nouveaux derives de 2-pyridinecarboxamide | |
| MA29323B1 (fr) | Composes de l'acide pyridylacetique | |
| ATE458483T1 (de) | Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung | |
| NO20065537L (no) | Heterosykliske amidforbindelser og anvendelse derav som en MMP-13-inhibitor | |
| YU44898A (sh) | Postupak za dobijanje magnezijumove soli supstituisanog heterocikličnog sulfinila | |
| BG105271A (bg) | Производни на 1h-имидазопиридин | |
| WO2006078621A3 (fr) | Composes heteroaryle tenant lieu d'inhibiteurs du recepteur p2y1 | |
| MA30524B1 (fr) | Agent de lutte antiparasite contenant un nouveau derive de pyridyl-methanamine ou un sel de celui-ci | |
| WO2004004730A3 (fr) | Composes pharmaceutiques | |
| MA32642B1 (fr) | Amides utiles en therapie | |
| US4978670A (en) | Anthelmintic quaternaryalkyl acylhydrazones, method of use and compositions | |
| MY137761A (en) | The use of n-arylhdrazine derivatives for combating non-crop pests | |
| CA3074139A1 (fr) | Composes et compositions pour l'inhibition de ire1 | |
| Corte et al. | Pyridine and pyridinone-based factor XIa inhibitors | |
| ATE491704T1 (de) | 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten | |
| RU2307829C2 (ru) | Карбоксамидные производные амидного типа | |
| Conroy et al. | Piperazines. III. 1-Heterocyclic-4-Guanyl-, Carbamyl-, and Thiocarbamyl-Piperazines | |
| NO20033660D0 (no) | HIV inhibitere N-aminoimidazolderivativer | |
| Carson et al. | 2-Amino-5-aryl-2-oxazolines. Tautomerism, stereochemistry, and an unusual reaction | |
| EP1908752A4 (fr) | Nouveau dérivé de 2-quinolone | |
| US4929744A (en) | Process for preparing heteroaromatic methyl)-2,2'-bi-1H-imidazoles | |
| CA1338786C (fr) | (aryle ou methyle heteroaromatique)-2,2'-bi- 1h-imidazoles | |
| US3910914A (en) | 5-Heterocyclic-1,2,3,6-tetrahydro-4(5H)-pyrimidinethiones and pyrimidinone intermediates therefor | |
| TH82581B (th) | สารสำหรับป้องกันหรือรักษาโรคเส้นประสาท |